Financhill
Back

Relay Therapeutics Vs. Sarepta Therapeutics Industry Stock Comparison

Sell
24

RLAY
Relay Therapeutics

Last Price:
4.80
Seasonality Move:
-7.25%
Sell
49

SRPT
Sarepta Therapeutics

Last Price:
138.01
Seasonality Move:
14.88%
Sell
24
Relay Therapeutics (RLAY) is a Sell

Is Relay Therapeutics a Buy, Sell or Hold?

  • The current Relay Therapeutics [RLAY] share price is $4.76. The Score for RLAY is 24, which is 52% below its historic median score of 50, and infers higher risk than normal.
  • RLAY is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
49
Sarepta Therapeutics (SRPT) is a Sell

Is Sarepta Therapeutics a Buy, Sell or Hold?

  • The current Sarepta Therapeutics [SRPT] share price is $130.50. The Score for SRPT is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.
  • SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.

RLAY Stock Price Chart

What is Relay Therapeutics's stock price today?

  • The Relay Therapeutics share price today is $4.76
    Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and RLAY is experiencing slight selling pressure.

SRPT Stock Price Chart

What is Sarepta Therapeutics's stock price today?

  • The Sarepta Therapeutics share price today is $130.50
    Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SRPT is experiencing buying pressure, which is a positive indicator for future bullish movement.

RLAY Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.45 Sell
Relative Strength Index (14 RSI): 29.55 Sell
Chaikin Money Flow: -163511 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (5.03 - 6.17) Sell
Bollinger Bands (100): (5.8 - 8.02) Sell

SRPT Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -2.3 Sell
Relative Strength Index (14 RSI): 64.59 Buy
Chaikin Money Flow: 3149400 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (111.02 - 128.88) Buy
Bollinger Bands (100): (119.18 - 142.3) Sell

RLAY Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 4.81 Sell
20-day SMA: 5.48 Sell
50-day SMA: 6.26 Sell
200-day SMA: 7.27 Sell
8-day EMA: 4.93 Sell
20-day EMA: 5.38 Sell
50-day EMA: 6.03 Sell
200-day EMA: 7.41 Sell

SRPT Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 112.07 Buy
20-day SMA: 117.27 Buy
50-day SMA: 121.92 Buy
200-day SMA: 129.99 Buy
8-day EMA: 116.28 Buy
20-day EMA: 117.14 Buy
50-day EMA: 121.91 Buy
200-day EMA: 125.98 Buy

Relay Therapeutics Earnings Growth & RLAY Earnings Dates

  • Analysts estimate an earnings increase this quarter of $0.15 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.36 per share, and a decrease next year of $0.02 per share.

Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates

  • Analysts estimate an earnings increase this quarter of $2.87 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.84 per share, and an increase next year of $8.76 per share.

Relay Therapeutics Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Sarepta Therapeutics Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):